Christina Cheddar Berk

Eli Lilly’s ‘diabesity’ medications are positioning it to become the first pharmaceutical company to hit $1 trillion in market cap, Morgan Stanley said.

Elanco CEO Jeff Simmons expects the company to debut six products over the next two years that will each see more than $100 million in peak sales.

Ozempic and Wegovy have been cheered for helping people shed unwanted pounds, but the findings of a recent poll underscore the challenges patients face.

Oprah Winfrey has changed her mind on weight loss drugs and others have, too. What’s ahead for the category in 2024.

Investors are contemplating where and when the next big obesity drug deal will occur.

Shoppers are worn down by inflation, but investors are wary of retailers that could get whacked by falling prices.

Deutsche Bank analyst James Shin says there are several reasons why Lilly should trade at a premium to Novo Nordisk.

Companies — both big and small — are hoping to grab a piece of the lucrative anti-obesity drug market. Piper Sandler counts 78 agents in development.

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative. Here’s why.

Piper Sandler analyst Allison Bratzel said the loss of lean muscle while taking GLP-1 drugs is “a major shortcoming” that could have bigger consequences.

Investors are making a lot of bets about GLP-1 drugs, but what if those hunches are incorrect?

GLP-1 medications could have far-reaching implications for a wide variety of conditions, from liver disease to sleep apnea to heart disease.

The eye-popping predictions for weight loss drug sales hinge on insurance coverage of the pricey treatments, and momentum seems to be building on that front.

Shares in the maker of medicines for pets and livestock are off 10% since their peak in late July, but investors may be overlooking a key product launch.

Evercore ISI initiated coverage of an immunology and inflammation drug developer at an outperform, saying the market is underpricing its odds for success.

A fit population would have different habits that could ripple through the economy and eventually be felt by the real estate industry, Jefferies predicts.

The popularity of new diabetes and weight loss drugs have been bad news for diabetes device makers, but the news may not be all bad.

A number of early-stage drug delivery companies are flying under investors’ radar. Some can help patients avoid injections or IVs.

While Novo Nordisk’s Select study stoked confidence in the weight loss drug market, it spooked holders of medtech and liver disease stocks seen losing out.

As Alzheimer’s patients seek treatment, they will need MRIs, blood tests and other diagnostics, fueling increased demand for these important tools.